Drug Trial Radar · NCT00233402
Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy
Last checked: Nov 20, 2026Latest source record: Oct 11, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
789
Actual
Start
Jan 2005
Primary completion
Jul 2008
Study completion Aug 2008
Sponsor
- Lead sponsor
- PhotocureIndustry
- Sponsor type
- Industry
- First posted
- Oct 5, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to document the additional detection of papillary bladder cancer and the reduced early recurrence due to the improved detection and resection of these tumors after Hexvix cystoscopy compared to standard cystoscopy in patients with papillary bladder cancer.
Conditions
- Bladder Cancer
Interventions
HexvixDrug
Single Instillation, Transurethral Resection of the Bladder
Standard white light cystoscopyProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients With >= 1 Ta or T1 Tumor Detected With Blue Light and Not White LightTime frame: Day 0
- Comparison of the Proportions of Patients in the White Light Cystoscopy and Hexvix Groups Who Underwent TURB for a Histologically-confirmed Ta or T1 Tumor Who Had a Recurrence ( CIS, Ta, T1 or T2-T4 Tumor) Within 9 Months.Time frame: 9 months
Locations
25 sites in 5 countries. Site status is shown where the registry gives one.
Stanford Cancer Center, Department of Urology
Stanford, California
V.A. Medical Center
Gainesville, Florida
University of Miami School of Medicine
Miami, Florida
South Florida Clinical Research Center, Inc.
Pembroke Pines, Florida
The Emory Clinic, Dept of Urology
Atlanta, Georgia
Boston University School of Medicine
Boston, Massachusetts
St. Joseph Mercy Hospital- Ann Arbor
Ann Arbor, Michigan
Urologic Clinical Research Unit, Gonda 7102, Mayo Clinic Rochester
Rochester, Minnesota
Hackensack University Medical Center
Hackensack, New Jersey
Mount Sinai Medical Center, Department of Urology
New York, New York
URMC
Rochester, New York
Urological Institute at Beachwood Cleveland Clinic
Beachwood, Ohio
Thomas Jefferson Medical College, Department of Neurology
Philadelphia, Pennsylvania
Vanderbilt University Medical Center, Department of Urologic Surgery
Nashville, Tennessee
Baylor College of Medicine, Scott Department of Urology
Houston, Texas
AKH, Klinik für Urologie der Universität Wien
Vienna, Austria
CHUQ Hotel-Dieu de Quebec
Québec, Canada
Kingston General Hospital
Kingston, Ontario, Canada
University Clinic of Giessen, Department of Urology
Giessen, Germany
Klinikum der Universität München-Großhardern, Urologische Klinik und Poliklinik
München, Germany
Urologische Klinik München-Planegg
Planegg, Germany
Akadem. Lehrkrankenhaus der Uni Regensburg, Klinik für Urologie
Regensburg, Germany
Universitätsklinik Tuebingen, Universitätsklinik für Urologie
Tübingen, Germany
Department of Urology, Academic Medical Center, University of Amsterdam
Amsterdam, Netherlands
Department of Urology, UMC St. Radboud
Nijmegen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.